Total hip and knee replacement surgeries are associated with a high risk of developing blood clots within a vein (venous thromboembolism) that can cause heart attack, stroke, and other serious conditions. Patients are usually given preventative anticoagulant medications. Traditionally, low molecular-weight heparins administered by subcutaneous injection have been used; more recently, new oral anticoagulants have been developed.
This study revealed that the model structures and clinical events used in the economic analyses were fairly consistent, and strongly suggested that new oral anticoagulants are cost-effective alternatives to low molecular-weight heparins.
Corresponding author James Brockbank, MSc, is a Senior Research Health Economist at RTI-HS in Manchester, UK. Sorrel Wolowacz, PhD, is Head of European Health Economics at RTI HS with 15 years of experience in heath economics consulting and 25 years of experience in the health care industry, including health outcomes, clinical research, and product development.